interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Tapinarof

Generic competition · all medicines · read 12 November 2026

Is there a generic of Tapinarof, and who makes it?

Tapinarof appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Tapinarof1 dosage-form group in the Orange Book
0generic makers listed
  1. Tapinarof appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Cream, Topical

Brand listed, no generic listed as marketed

Brand listed as marketed: Vtama. No generic is listed as marketed.

2020202520302035204001brand 2022data datePatent 10426743 listed to expire 19 May 2036Patent 11612573 listed to expire 19 May 2036Patent 11617724 listed to expire 19 May 2036Patent 11622945 listed to expire 19 May 2036Patent 11458108 listed to expire 19 May 2036Patent 10195160 listed to expire 23 May 2036Patent 10647649 listed to expire 13 November 2038Patent 11597692 listed to expire 13 November 2038Patent 11590088 listed to expire 13 November 2039Patent 11497718 listed to expire 13 November 2039Patent 11938099 listed to expire 13 November 2039Patent 12569453 listed to expire 18 December 2039Exclusivity NCE to 23 May 2027Exclusivity I-956 to 12 December 2027
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 23 May 2027Exclusivity NCE Vtama
  • 12 December 2027Exclusivity I-956 Vtama
  • 19 May 2036Patent 10426743
  • 19 May 2036Patent 11612573
  • 19 May 2036Patent 11617724 drug product
  • 19 May 2036Patent 11622945 drug product
  • 19 May 2036Patent 11458108 drug product
  • 23 May 2036Patent 10195160 drug product
  • 13 November 2038Patent 10647649 drug substance
  • 13 November 2038Patent 11597692 drug substance

4 more patents are listed.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.